Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.

Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WM, Lin EH, Cohn DE, Goodfellow PJ, Arnold MW, de la Chapelle A, Pearlman R, Hampel H, Pritchard CC.

Gastroenterology. 2016 Sep;151(3):440-447.e1. doi: 10.1053/j.gastro.2016.06.004. Epub 2016 Jun 11.

2.

Improving performance of multigene panels for genomic analysis of cancer predisposition.

Shirts BH, Casadei S, Jacobson AL, Lee MK, Gulsuner S, Bennett RL, Miller M, Hall SA, Hampel H, Hisama FM, Naylor LV, Goetsch C, Leppig K, Tait JF, Scroggins SM, Turner EH, Livingston R, Salipante SJ, King MC, Walsh T, Pritchard CC.

Genet Med. 2016 Oct;18(10):974-81. doi: 10.1038/gim.2015.212. Epub 2016 Feb 4.

PMID:
26845104
3.

DNA Yield From Tissue Samples in Surgical Pathology and Minimum Tissue Requirements for Molecular Testing.

Austin MC, Smith C, Pritchard CC, Tait JF.

Arch Pathol Lab Med. 2016 Feb;140(2):130-3. doi: 10.5858/arpa.2015-0082-OA. Epub 2015 Jun 22.

PMID:
26098132
4.

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.

Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS.

Nat Commun. 2014 Sep 25;5:4988. doi: 10.1038/ncomms5988.

5.

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.

Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, Wu D, Lee MK, Dintzis S, Adey A, Liu Y, Eaton KD, Martins R, Stricker K, Margolin KA, Hoffman N, Churpek JE, Tait JF, King MC, Walsh T.

J Mol Diagn. 2014 Jan;16(1):56-67. doi: 10.1016/j.jmoldx.2013.08.004. Epub 2013 Nov 2.

6.

Plasma processing conditions substantially influence circulating microRNA biomarker levels.

Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M, Pritchard CC.

PLoS One. 2013 Jun 7;8(6):e64795. doi: 10.1371/journal.pone.0064795. Print 2013.

7.

ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Pritchard CC, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher EM, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King MC, Tait JF, Walsh T.

J Mol Diagn. 2012 Jul;14(4):357-66. doi: 10.1016/j.jmoldx.2012.03.002. Epub 2012 May 30.

8.

Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.

Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M.

Cancer Prev Res (Phila). 2012 Mar;5(3):492-497. doi: 10.1158/1940-6207.CAPR-11-0370. Epub 2011 Dec 12.

9.

A new microparticle size calibration standard for use in measuring smaller microparticles using a new flow cytometer.

Chandler WL, Yeung W, Tait JF.

J Thromb Haemost. 2011 Jun;9(6):1216-24. doi: 10.1111/j.1538-7836.2011.04283.x.

10.

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.

Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8. doi: 10.1073/pnas.1019055108. Epub 2011 Mar 7.

11.

COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma.

Pritchard CC, Akagi L, Reddy PL, Joseph L, Tait JF.

BMC Clin Pathol. 2010 Nov 26;10:6. doi: 10.1186/1472-6890-10-6.

12.

Annotation error of a common β°-thalassemia mutation (619 bp-deletion) has implications for molecular diagnosis.

Pritchard CC, Tait JF, Buller-Burckle AM, Mikula M.

Am J Hematol. 2010 Dec;85(12):978. doi: 10.1002/ajh.21875. No abstract available.

13.

Characterization of a recombinant form of annexin VI for detection of apoptosis.

Smith C, Mehta R, Gibson DF, Levashova Z, Blankenberg FG, Tait JF.

Bioconjug Chem. 2010 Aug 18;21(8):1554-8. doi: 10.1021/bc100239k.

PMID:
20672837
14.

Transmembrane voltage regulates binding of annexin V and lactadherin to cells with exposed phosphatidylserine.

Smith C, Gibson DF, Tait JF.

BMC Biochem. 2009 Feb 17;10:5. doi: 10.1186/1471-2091-10-5.

15.

Imaging of apoptosis.

Tait JF.

J Nucl Med. 2008 Oct;49(10):1573-6. doi: 10.2967/jnumed.108.052803. Epub 2008 Sep 15. Review.

16.

Site-specific labeling of annexin V with F-18 for apoptosis imaging.

Li X, Link JM, Stekhova S, Yagle KJ, Smith C, Krohn KA, Tait JF.

Bioconjug Chem. 2008 Aug;19(8):1684-8. doi: 10.1021/bc800164d. Epub 2008 Jul 16.

17.

Entropic and enthalpic contributions to annexin V-membrane binding: a comprehensive quantitative model.

Jeppesen B, Smith C, Gibson DF, Tait JF.

J Biol Chem. 2008 Mar 7;283(10):6126-35. doi: 10.1074/jbc.M707637200. Epub 2008 Jan 3.

18.

Effect of postconditioning on myocardial 99mTc-annexin-V uptake: comparison with ischemic preconditioning and caspase inhibitor treatment.

Taki J, Higuchi T, Kawashima A, Fukuoka M, Kayano D, Tait JF, Matsunari I, Nakajima K, Kinuya S, Strauss HW.

J Nucl Med. 2007 Aug;48(8):1301-7. Epub 2007 Jul 13.

19.

(99m)Tc-Annexin-V uptake in a rat model of variable ischemic severity and reperfusion time.

Taki J, Higuchi T, Kawashima A, Tait JF, Muramori A, Matsunari I, Nakajima K, Vanderheyden JL, Strauss HW.

Circ J. 2007 Jul;71(7):1141-6.

20.

Utilization and diagnostic yield of neurogenetic testing at a tertiary care facility.

Edlefsen KL, Tait JF, Wener MH, Astion M.

Clin Chem. 2007 Jun;53(6):1016-22. Epub 2007 Apr 19.

21.

Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis.

Blankenberg FG, Vanderheyden JL, Strauss HW, Tait JF.

Nat Protoc. 2006;1(1):108-10.

PMID:
17406220
22.

Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods.

Tait JF, Smith C, Levashova Z, Patel B, Blankenberg FG, Vanderheyden JL.

J Nucl Med. 2006 Sep;47(9):1546-53.

23.

Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice.

Vanderheyden JL, Liu G, He J, Patel B, Tait JF, Hnatowich DJ.

Nucl Med Biol. 2006 Jan;33(1):135-44.

PMID:
16459269
24.

Structural requirements for in vivo detection of cell death with 99mTc-annexin V.

Tait JF, Smith C, Blankenberg FG.

J Nucl Med. 2005 May;46(5):807-15.

25.
26.

Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis.

Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, Gibson DF, Krohn KA.

J Nucl Med. 2005 Apr;46(4):658-66.

27.

Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-annexin V uptake and histologic findings in an experimental model.

Takei T, Kuge Y, Zhao S, Sato M, Strauss HW, Blankenberg FG, Tait JF, Tamaki N.

J Nucl Med. 2004 Dec;45(12):2083-7.

28.

The effect of common clinical contaminants on amniotic fluid fluorescence polarization results.

Srouji SS, Carr DB, Gardella CM, Benedetti T, Tait JF.

Obstet Gynecol. 2004 Dec;104(6):1237-43.

PMID:
15572483
29.

Detection of cardiomyocyte death in a rat model of ischemia and reperfusion using 99mTc-labeled annexin V.

Taki J, Higuchi T, Kawashima A, Tait JF, Kinuya S, Muramori A, Matsunari I, Nakajima K, Tonami N, Strauss HW.

J Nucl Med. 2004 Sep;45(9):1536-41.

30.

Essential role of B-helix calcium binding sites in annexin V-membrane binding.

Jin M, Smith C, Hsieh HY, Gibson DF, Tait JF.

J Biol Chem. 2004 Sep 24;279(39):40351-7. Epub 2004 Jul 26.

31.

Nuclear medicine in the era of genomics and proteomics: lessons from annexin V.

Belhocine TZ, Tait JF, Vanderheyden JL, Li C, Blankenberg FG.

J Proteome Res. 2004 May-Jun;3(3):345-9.

PMID:
15253415
32.

Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death.

Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC.

Nucl Med Biol. 2004 Aug;31(6):747-52.

PMID:
15246365
33.

Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome.

Mandl SJ, Mari C, Edinger M, Negrin RS, Tait JF, Contag CH, Blankenberg FG.

Mol Imaging. 2004 Jan;3(1):1-8.

PMID:
15142407
34.
35.

The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function.

Tait SA, Tait JF, Coghlan JP.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):1-21.

PMID:
15134795
36.

Production of [F-18]fluoroannexin for imaging apoptosis with PET.

Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, Link JM, Krohn KA.

Bioconjug Chem. 2004 Mar-Apr;15(2):373-9.

PMID:
15025534
37.

Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V.

Mari C, Karabiyikoglu M, Goris ML, Tait JF, Yenari MA, Blankenberg FG.

Eur J Nucl Med Mol Imaging. 2004 May;31(5):733-9. Epub 2004 Feb 21.

PMID:
14985868
38.

Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model.

Kuge Y, Sato M, Zhao S, Takei T, Nakada K, Seki KI, Strauss HW, Blankenberg FG, Tait JF, Tamaki N.

J Nucl Med. 2004 Feb;45(2):309-12.

39.

18F-labelled annexin V: a PET tracer for apoptosis imaging.

Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, Tait JF, Nishimura S.

Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):469-74. Epub 2003 Dec 10.

PMID:
14666384
40.

99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis.

Tokita N, Hasegawa S, Maruyama K, Izumi T, Blankenberg FG, Tait JF, Strauss HW, Nishimura T.

Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):232-8. Epub 2002 Nov 14.

PMID:
12552341
41.

Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V.

Mochizuki T, Kuge Y, Zhao S, Tsukamoto E, Hosokawa M, Strauss HW, Blankenberg FG, Tait JF, Tamaki N.

J Nucl Med. 2003 Jan;44(1):92-7.

42.

Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis.

Post AM, Katsikis PD, Tait JF, Geaghan SM, Strauss HW, Blankenberg FG.

J Nucl Med. 2002 Oct;43(10):1359-65.

43.

Development of annexin V mutants suitable for labeling with Tc(i)-carbonyl complex.

Tait JF, Smith C, Gibson DF.

Bioconjug Chem. 2002 Sep-Oct;13(5):1119-23.

PMID:
12236794
44.

In vivo imaging of acute cardiac rejection in human patients using (99m)technetium labeled annexin V.

Kown MH, Strauss HW, Blankenberg FG, Berry GJ, Stafford-Cecil S, Tait JF, Goris ML, Robbins RC.

Am J Transplant. 2001 Sep;1(3):270-7.

45.

Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats.

Blankenberg FG, Wen P, Dai M, Zhu D, Panchal SN, Tait JF, Post AM, Strauss HW, Valantine HA.

Pediatr Radiol. 2001 Dec;31(12):827-35.

PMID:
11727015
46.

Annexin-V imaging for noninvasive detection of cardiac allograft rejection.

Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, Fitzpatrick JM, Raghunath PN, Tomaszewski JE, Kelly C, Steinmetz N, Green A, Tait JF, Leppo J, Blankenberg FG, Jain D, Strauss HW.

Nat Med. 2001 Dec;7(12):1347-52.

PMID:
11726976
47.
48.

Apoptosis and allograft rejection in the absence of CD8+ T cells.

Ogura Y, Martinez OM, Villanueva JC, Tait JF, Strauss HW, Higgins JP, Tanaka K, Esquivel CO, Blankenberg FG, Krams SM.

Transplantation. 2001 Jun 27;71(12):1827-34.

PMID:
11455265
49.

Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V.

Blankenberg FG, Naumovski L, Tait JF, Post AM, Strauss HW.

J Nucl Med. 2001 Feb;42(2):309-16.

50.

Development and characterization of annexin V mutants with endogenous chelation sites for (99m)Tc.

Tait JF, Brown DS, Gibson DF, Blankenberg FG, Strauss HW.

Bioconjug Chem. 2000 Nov-Dec;11(6):918-25.

PMID:
11087342

Supplemental Content

Support Center